Evidence map›Paper›PMID 40972238›Full record

ArticleVaccine2025

Assessment of critical bioprocess parameters for broadly cross-reactive chimeric hemagglutinin influenza virus vaccines.

Michael J Scherm, Robert Hölzl, Irene González-Domínguez, Richard Hjorth, Sean S Chiou, Maureen F Maughan, Diana Martik, Florian Krammer, Eduard Puente-Massaguer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael J SchermDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Robert HölzlDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Irene González-DomínguezDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Richard HjorthGlobal Project Services Inc., Tampa, FL 33609, USA.
Sean S ChiouDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Maureen F MaughanDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Diana MartikDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Science Outreach and Pandemic Preparedness at the Medical University of Vienna, Vienna, Austria. Electronic address: florian.krammer@mssm.edu.
Eduard Puente-MassaguerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address: eduard.puente-massaguer@mssm.edu.

Funding

COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4M
NIH HHS 75N93019C00051
6 · The paper itself

Abstract

Antigenic drift of seasonal influenza viruses and unpredictable outbreaks with new influenza virus subtypes are a global concern that requires the development of broadly protective vaccines. We previously showed that chimeric hemagglutinin (cHA) virus vaccines are an effective strategy to elicit cross-protective immune responses to the conserved hemagglutinin (HA) stalk domain. However, the critical bioprocess parameters and vaccine quality attributes for cHA inactivated split constructs remain to be defined. Here, we developed an egg-based bioprocess for inactivated virus vaccine production with special focus on group 2 cHA viruses (cH15/3

Indexed as

Hemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesAnimalsAntibodies, ViralCross ReactionsMiceOrthomyxoviridae InfectionsVaccines, InactivatedVaccines, SyntheticVirus InactivationAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza VaccinesVaccines, InactivatedVaccines, Syntheticbeta-propiolactonecHAHA stalkNANeuraminidaseTriton X-100Vaccine stability

Identifiers

PMID40972238
PMCPMC13393470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.